ArticlemBio2019
Genome-Wide Screening for Enteric Colonization Factors in Carbapenem-Resistant ST258 Klebsiella pneumoniae.
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 50 citations in OpenAlex.
- A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects.The Journal of antimicrobial chemotherapy · 2020Trial
- An atlas of colonization factors in the human gut microbiome reveals ecological strategies and inflammatory bowel disease signatures.Nature communications · 2026Article
- A posttranslational modification of fimbriae drives pathogenicity inProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Sugar import suppresses Klebsiella pneumoniae Mucoidy in a cAMP-CRP-dependent manner.Nature communications · 2026Article
- Resident and EngraftingbioRxiv : the preprint server for biology · 2026Article
- Genome-wide analysis exploring mechanisms used bymSystems · 2026Article
- Article
- Klebsiella pneumoniae employs a type VI secretion system to overcome microbiota-mediated colonization resistance.Nature communications · 2025Article
- Rapid design of bacteriophage cocktails to suppress the burden and virulence of gut-resident carbapenem-resistant Klebsiella pneumoniae.Cell host & microbe · 2024Article
- Deciphering the gastrointestinal carriage ofInfection and immunity · 2024Review
- Article
- Transposon mutagenesis screen ineLife · 2024Article
- Study of the Genomic Characterization of Antibiotic-ResistantIndian journal of microbiology · 2024Article
- sRNA expression profile of KPC-2-producing carbapenem-resistant Klebsiella pneumoniae: Functional role of sRNA51.PLoS pathogens · 2024Article
- Associations between Nutrigenomic Effects and Incidences of Microbial Resistance against Novel Antibiotics.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Hypermucoviscous Carbapenem-ResistantInternational journal of molecular sciences · 2023Article
- Occurrence and Molecular Study of Hypermucoviscous/Hypervirulence Trait in Gut CommensalMicroorganisms · 2023Article
- Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.Microbiology spectrum · 2022Article
- Klebsiella pneumoniae l-Fucose Metabolism Promotes Gastrointestinal Colonization and Modulates Its Virulence Determinants.Infection and immunity · 2022Article
- Lactobacillus supports Clostridiales to restrict gut colonization by multidrug-resistant Enterobacteriaceae.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
A diverse, antibiotic-naive microbiota prevents highly antibiotic-resistant microbes, including carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.